| Status | Awaiting development |
| Technology type | Medicine |
| Decision | None selected |
| Process | STA Standard |
| ID number | 3996 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 09 February 2024 | Suspended. For information, the company have announced that the STIMULUS program for Sabatolimab with azacitidine for untreated high-risk myelodysplastic syndromes has been terminated and therefore they will no longer be pursuing a Marketing Authorisation Application in this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes. |
| 09 February 2024 | Awaiting development. For information, the company have announced that the STIMULUS program for Sabatolimab with azacitidine for untreated high-risk myelodysplastic syndromes has been terminated and therefore they will no longer be pursuing a Marketing Authorisation Application in this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes. |
| 15 July 2022 | Following on from advice received from the company this appraisal will be rescheduled to align with latest regulatory expectations. Further information regarding the timelines for this appraisal will be available in due course. |
For further information on our processes and methods, please see our CHTE processes and methods manual